Sign up Australia
Proactive Investors - Run By Investors For Investors

Avacta Group “significant technical and commercial” headway

Avacta said it has developed multiple PD-L1 inhibitors, which are designed to use the body's own immune system to battle cancer
Lab technician
The company said its technology showed a “clear indication of efficacy”

Avacta Group Plc (LON:AVCT) said it is making “significant technical and commercial” headway with its Affimer technology as it updated on its progress.

Affimers are small, engineered proteins, some of which are of human origin and some of plant origin, and are capable of binding specific molecular targets in a similar way to antibodies.

Avacta in its announcement said it has developed multiple PD-L1 inhibitors as part of its immuno-oncology programme and has selected the most promising candidate to go forward to first-in-man clinical trial in 2019.

READ: The trading update in full

It said its technology showed a “clear indication of efficacy” in industry-standard mouse syngeneic models.

The discovery programme is delivering a pipeline of Affimer binders to other important immuno-oncology targets, it added.

Complementing its own in-house programme, Avacta also has a partnership with Moderna Therapeutics, as well as collaborations with the Sloan Kettering Cancer Center in New York and Newcastle-based Glythera Ltd.

In a comprehensive update, Avacta also reported strong growth in its pipeline of paid-for Affimer-based research with the order book up 64% year-on-year.

“I am delighted that we have been able to report the signing of the first agreement for Affimer product development following a technology evaluation by one of the world's largest diagnostics developers,” said chief executive, Dr Alastair Smith.

“A number of other evaluations are advancing positively and we believe that these will lead to further licensing deals which would result in long term royalty based revenue growth from non-therapeutic applications.”

Financially, the company is making headway with revenues up 27% in the year to July 31 at £2.75mln. The loss was £7.9mln, but more importantly Avacta’s cash position was well ahead of market expectations at £13mln.

The technology in detail

Avacta has developed an innovative protein-scaffold platform, with potential applications in the life sciences research, diagnostic and therapeutic markets.

Named Affimers, the scaffolds are essentially small, engineered proteins, some of which are of human origin and some of plant origin, capable of binding specific molecular targets, in a similar way to antibodies.

However, compared with antibodies, Affimers have several innovative and distinctive features, which could potentially make them a better tool for several diagnostic and therapeutic applications.

They are smaller, quicker to manufacture and easier to format, but they maintain antibody-like biologic activity when binding a target.

Commercial potential

In order to maximise the potential of the technology, Avacta is pursuing a development strategy based on two business lines:

-         Servicing the life sciences research and diagnostic industry with customised Affimer reagents

-         Using Affimers as the core of a potential new generation of drugs

Avacta plans to commercialise Affimer reagents by licensing them to a broad range of clients in the bio-pharmaceutical and diagnostic industry.

“Based on the data generated by the ongoing tests with a wide range of third parties, we believe it is reasonable to expect that the first commercial deal could be signed before the end of 2017,” said Dr Riccardo Lowi, analyst at the research firm Capital Networks.



Ian_55ae0ddd437b7.jpg
Why Invest In Avacta Group Plc? Read More Here

Register here to be notified of future AVCT Company articles
View full AVCT profile View Profile

Avacta Group Plc Timeline

Related Articles

blood cells
October 24 2017
“We are delighted to report positive results from the Phase II study. We believe PeproStat is a first-in-class product which could enter the large and growing haemostat market as early as 2020.”
scientist in a lab
September 28 2017
“I strongly believe that ValiRx and its assets offer investors or joint venture partners an increasingly attractive and investable proposition as we strengthen our position among frontrunners in the fields of personalised and precision medicine"
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use